NCT04065633 - Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

December 14, 2019

Study Completion Date

December 14, 2019

Conditions

Dermatitis, Atopic

Interventions

DRUG

P3-Fast

200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions

DRUG

Comm-Fast

200 mg PF-04965842 commercial tablet formulation under fasted conditions

DRUG

Vari-Fast

200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions

DRUG

Comm-Fed

200 mg PF-04965842 commercial tablet formulation under fed conditions

Trial Locations (1)

New Haven Clinical Research Unit, New Haven